INTRODUCTION
============

It is widely accepted that antibodies against the TSH receptor may play an important role in the cause of hyperthyroidism in Graves' disease^[@b1-kjim-5-1-51-7])^. The activity of these antibodies can be estimated by direct biological activity, termed thyroid stimulating antibody (TSAb), or by their ability to inhibit the binding of radiolabeled thyrotropin to thyroid membranes, termed thyrotropin binding inhibitor immunoglobulins (TBII). It has recently been reported that immunoglobulins in primary nongoitrous myxedema not only inhibit the binding of TSH to its receptor, but also inhibit TSH-stimulated adenylate cyclase activation in cultured thyroid cells^[@b2-kjim-5-1-51-7],[@b3-kjim-5-1-51-7])^, and these thyroid stimulation blocking antibodies (TSBAb) may play a role in the development of hypothyroidism and thyroid atrophy in primary nongoitrous myxedema^[@b4-kjim-5-1-51-7])^.

After radioiodine treatment for Graves' hyperthyroidism, a transient increase, followed by a decline in TSH receptor antibodies (TRAb), has been well-documented^[@b5-kjim-5-1-51-7]--[@b9-kjim-5-1-51-7])^. Recently, it has been reported that TSBAb develop in patients with Graves' disease during antithyroid drug treatment^[@b10-kjim-5-1-51-7])^ or after radioiodine treatment^[@b11-kjim-5-1-51-7],[@b12-kjim-5-1-51-7])^. However, it is still uncertain whether changes in the properties of TRAb after radioiodine treatment, especially development of TSBAb, could alter the clinical outcome of Graves' disease.

In the present study, we simultaneously meausred TBII, TSAb and TSBAb activities sequentially after a single dose of ^131^I and compared their activities with the functional status of the thyroid in patients with Graves' disease.

MATERIALS AND METHODS
=====================

1.. Patients
------------

Twenty-one patients (10 male, 11 female), ranging in age from 15 to 72 years (mean age: 42 years), were studied. The diagnosis of Graves' hyperthyroidism was based on clinical findings, elevated serum T4 level, decreased serum TSH level and increased thyroidal ^131^I uptake. No patients had been previously treated with ^131^I. Six of the patients received ^131^I as the first-line therapy, and the remainder were treated with antithyroid drugs for 12--70 months before ^131^I treatment.

Thyroid weight was estimated by palpation and scintiscan, and 100--150 uCi of ^131^I per gram of thyroid tissue was administered (4--15 mCi, mean±SD: 9.1±2.1 mCi). All patients were treated with methimazole for one or two months after the ^131^I administration, and if a relapse occurred, antithyroid medications were given until the completion of the study. After radioiodine treatment, blood samples were taken at three-month intervals up to 12 months. The IgG fraction was isolated from the serum samples by means of affinity chromatography on columns of protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden). Thyroid function tests were done with commercially available RIA kits.

2.. Assay for TBII
------------------

TBII was measured as previously described^[@b13-kjim-5-1-51-7])^ using a commercial radioreceptor assay kit (R.S.R. Ltd., Cardiff, Wales, UK). TBII activity was expressed as the percent inhibition of ^125^I-bTSH binding to the TSH receptor. A TBII value exceeding 20% was considered abnormal or positive.

3.. Assay for TSAb and TSBAb
----------------------------

FRTL-5 cells, kindly supplied by Dr. L.D. Kohn (NIH, Bethesda, MD., USA), were maintained as previously described^[@b14-kjim-5-1-51-7])^ and also maintained for seven days in a medium without TSH before the assay. The medium was changed with 300 ul of test IgG (10 g/l). IgGs were dissolved in Hank's balanced salt solution (HBSS) without NaCl containing 0.5 mmol/l IBMX, 20 mmol/l HEPES, and 1.0% BSA, pH 7.4. After 2 h incubation at 37°C, cAMP released into the medium was measured by RIA (Immunonuclear, Stillwater, Minn., USA). The assay system was sensitive to 5 mU/l bTSH with a response of 1.71±0.07 times the basal cAMP level. All samples were run in triplicate. The intrassay variance was 8.2--12.1%, and the interassay variance was 17.1--30.5%. TSAb activity was expressed as a % increase in cAMP production by test IgG in comparison with normal IgG. TSAb was defined as positive when the value was greater than 2 SD above the mean value produced by the IgG fraction from 24 normal subjects (\>170%).

For the assay of TSBAb, test IgG was incubated with or without 0.1 U/l bTSH. Other procedures were the same as in the TSAb assay. TSBAb activity was expressed as a % inhibition of the TSH-stimulated cAMP increase and was calculated as follows: TSBAb (%) = 100 × \[1 − (cAMP under 0.1 U/l bTSH with test IgG-cAMP under normal IgG)/(cAMP under 0.1 U/l bTSH with normal IgG-cAMP under normal IgG)\]. TSBAb was defined as positive when the value was greater than 2 SD above the mean value produced by the IgG fractions from 24 normal subjects (\>37%).

4.. Statistical Analysis
------------------------

Statistical analysis was done with a Fisher's exact test and Wilcoxon rank sum test. Statistical significance was defined as having a P-value below 0.05.

RESULTS
=======

Before radioiodine treatment, TBII was detected in all 21 patients, and TSAb was detected in 19 out of 21. The individual changes of TBII and TSAb activities after radioiodine treatment were variable. TBII activities increased in six patients, decreased in six and remained unchanged in nine; TSAb activities increased in four, decreased in 11 and did not change in four patients during the 12-month observation period ([Table 1](#t1-kjim-5-1-51-7){ref-type="table"}, [Fig. 1](#f1-kjim-5-1-51-7){ref-type="fig"}). The changes of TBII and TSAb activities were not associated with pretreatment with antithyroid drugs ([Table 1](#t1-kjim-5-1-51-7){ref-type="table"}). At 12 months after radioiodine treatment, TBII was still present in all of the patients, but TSAb activity was not detected in eight patients, including the two in whom TSAb was undetectable before radioiodine treatment ([Table 1](#t1-kjim-5-1-51-7){ref-type="table"}). Between the patients whose TSAb activities persisted and those whose TSAb activities disappeared, there were no differences in age, sex, dose of ^131^I, duration of antithyroid drug treatment and titers of antimicrosomal and/or antithyroglobulin antibody. But TSAb activity before radioiodine treatment was significaltly higher in patients whose TSAb continued to persist than in those whose TSAb disappeared ([Table 2](#t2-kjim-5-1-51-7){ref-type="table"}).

Twelve months after radioiodine treatment, eight patients had become hypothyroid, 10 were in remission and three had relapsed. The patients' outcomes were not associated with TSAb activites at three and/or 12 months after radioiodine treatment. Pretreatment with antithyroid drugs did not affect the clinical outcome. Four out of eight patients who became hypothyroid were negative of TSAb activities. Of them, three patients had developed TSBAb during the observation peroid. All these patients became hypothyroid three to six months after radioiodine treatment, requiring thyroxine replacement ([Table 3](#t3-kjim-5-1-51-7){ref-type="table"}). Their TBII activities were potent before radioiodine administration and did not change after radioiodine treatment. But TSAb activities decreased gradually and disappeared within six months after radioiodine treatment, followed by a sudden appearance of TSBAb, coinciding with the development of hypothyroidism ([Fig. 2](#f2-kjim-5-1-51-7){ref-type="fig"}). TSBAb activities were not found in any of the patients before radioiodine treatment.

DISCUSSION
==========

In this study, we found that in contrast to previous reports^[@b8-kjim-5-1-51-7],[@b9-kjim-5-1-51-7])^ TBII persisted for 12 months after radioiodine treatment in all patients. This discrepancy may be due to the differences in the patients selected and the short observation period. Most of the patients in this study were resistant to the long-term antithyroid drug treatment and had high TBII activities before radioiodine treatment. Moreover, TBII activities did not change or decrease at three months after radioiodine treatment in 15 out of 21 patients. In this study, all the patients were treated with antithyroid drugs for two or more months after radioiodine treatment. Their use after radioiodine treatment may have prevented a transient increase in TRAb activities. Changes of TSAb activities after radioiodine treatment varied. TSAb activities did not change for 12 months in 13 out of 21 patients. However, in six patients TSAb activities decreased gradually and then disappeared, while TBII persisted in high titers. This dissociation between TSAb and TBII activities suggests the development of different types of antibodies against the TSH receptor.

An interesting finding in this study is the development of TSBAb after radioiodine treatment in three out of 21 patients with Graves' disease. All of them had both TBII and TSAb activities before radioiodine treatment. After radioiodine treatment, TSAb activities disappeared within six months and were followed by a sudden appearance of TSBAb activities. IgGs from these three patients inhibited not only the binding of TSH to its receptor but also a TSH-stimulated cAMP increase in FRTL-5 cells. Moreover, all of them developed hypothyroidism in accordance with the appearance of TSBAb. It is well-known that radioiodine therapy induces cell damage of the thyroid gland and results in hypothyroidism, but the present findings suggest that the appearance of TSBAb is in some cases related to the development of hypothyroidism.

The mechanism of changes in the properties of TRAb after radioiodine therapy in Graves' disease is still unknown. Since we had used antithyroid drugs for several months before radioiodine treatment, the potential effects of antithyroid drugs on the properties of TRAb and their activities should be considered. However, we could not find any correlation between the pretreatment with antithyroid drugs and the clinical outcome after radioiodine treatment. It may be speculated that radioiodine not only causes a release of large amounts of antigens but also alters immune homeostasis in the thyroid gland, resulting in changes in the properties of TRAb. Although the incidence of the development of TSAb after radioiodine therapy is not frequent, out findings suggest that thyroid function after radioiodine treatment in Graves' disease may be affected by changes in the properties of TRAb. Moreover, Furmaniak et al.^[@b15-kjim-5-1-51-7])^ recently described an interesting patient with Graves' disease who developed TSBAb and hypothyroidism after radioiodine treatment, and TSBAb disappeared spontaneously with a reappearance of TSAb and hyperthyroidism. The clinical status of Graves' disease might therefore be a result of the balance between the activities of stimulating and blocking types of TRAb^[@b16-kjim-5-1-51-7])^. Measuring several different actions of these TRAb might thus be of value in predicting the development of hypothyroidism in patients following radioiodine treatment.

![TBII (a) and TSAB (b) activities before and 12 months after radioiodine treatment in 21 patients with Gaves' disease. The shaded area represents the normal range.](kjim-5-1-51-7f1){#f1-kjim-5-1-51-7}

![Sequential changes in TBII, TSAb and TSBAb activities of three patients who developed TSBAb after radioiodine therapy. Closed circle: TSBAb, open circle: TSAb, closed rectangle: TBII. Closed arrows indicate the time when the patients became hypothyroid. The shaded area represents the normal range.](kjim-5-1-51-7f2){#f2-kjim-5-1-51-7}

###### 

Changes of TBII and TSAb Activities After Radioiodine Treatment in 21 Patients with Graves' Disease

  Patient Number                                       ^131^I (mCi)   TBII (%)   TSAb (%)   Clinical Outcome (months)                                                    
  ---------------------------------------------------- -------------- ---------- ---------- --------------------------- ------ ------ ------ ------ ------ ------ ------ -----------------
  Pretreatment with antithyroid drugs                                                                                                                                    
  1                                                    8              90.8       76.0       64.0                        66.1   69.0   258    168    178    245    301    Hypothyroid (9)
  2                                                    6              50.9       63.4       62.5                        61.9   51.9   494    2143   1340   993    630    Euthyroid
  3                                                    4              85.2       89.2       62.1                        63.5   31.9   403    217    356    326    218    Euthyroid
  4                                                    7              28.1       90.3       78.1                        70.0   62.1   222    425    401    365    359    Euthyroid
  5                                                    10             82.9       72.0       67.3                        81.9   90.0   385    365    365    1753   2469   Relapse (6)
  6                                                    12             77.8       78.2       89.8                        89.4   80.3   548    484    499    375    593    Relapse (12)
  7                                                    8              38.8       72.5       69.4                        78.8   78.0   2667   2104   2449   2716   2700   Euthyroid
  8                                                    8              39.6       68.4       78.4                        80.0   78.1   180    753    330    340    345    Hypothyroid (9)
  9                                                    10             81.4       91.2       95.8                        86.0   84.0   800    519    473    276    285    Hypothyroid (6)
  10                                                   8              55.2       89.8       82.4                        68.8   66.2   108    191    968    247    104    Relapse (6)
  11                                                   10             33.4       29.1       28.2                        26.5   26.0   79     79     83     105    109    Euthyroid
  12[^\*^](#tfn1-kjim-5-1-51-7){ref-type="table-fn"}   15             99.8       91.0       78.9                        80.5   76.0   394    321    84     109    133    Hypothyroid (3)
  13                                                   10             87.4       55.1       12.2                        37.9   32.0   454    404    104    84     104    Hypothyroid (9)
  14[^\*^](#tfn1-kjim-5-1-51-7){ref-type="table-fn"}   8              79.8       80.9       85.3                        80.4   55.7   316    237    168    109    100    Hypothyroid (6)
  15                                                   10             75.6       76.1       56.1                        37.0   30.3   4914   4490   3134   2245   545    Euthyroid
  No pretreatment with antithyroid drugs                                                                                                                                 
  16                                                   12             55.2       34.4       26.2                        30.5   35.5   5918   326    257    210    257    Euthyroid
  17                                                   10             75.0       57.9       41.9                        46.3   46.2   7347   6122   5714   380    347    Euthyroid
  18                                                   8              27.2       20.9       28.6                        23.2   25.1   180    85     83     99     85     Euthyroid
  19                                                   10             87.6       82.6       82.5                        82.5   82.0   2321   2874   3753   3805   3745   Hypothyroid (6)
  20[^\*^](#tfn1-kjim-5-1-51-7){ref-type="table-fn"}   10             90.0       80.5       71.3                        80.7   85.2   273    108    99     100    105    Hypothyroid (6)
  21                                                   8              71.3       59.7       51.3                        69.4   68.6   223    163    104    83     101    Euthyroid

Cases who developed TSAb after radioiodine treatment

###### 

Initial Clinical and Laboratory Data (mean ± SD) in TSAb Non--disappearing and TSAb Disappearing Groups

                                                        TSAb                                                                                                                   
  ----------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------- ---------
  Age                                                   44.2±13.3                                                    40.4±16.7                                                 NC
  Sex (M:F)                                             6 : 7                                                        4 : 4                                                     NC
  Goiter (g)                                            63.1±24.3                                                    61.3±21.0                                                 NC
  Dose of I (mCi)                                       8.9±2.3                                                      9.6±2.4                                                   NC
  Duration of ATD                                                                                                                                                              
  Treatment (months)                                    17.1±14.8                                                    29.0±28.2                                                 NC
  AMA[^\*^](#tfn3-kjim-5-1-51-7){ref-type="table-fn"}   4.0±1.6                                                      3.5±1.8                                                   NC
  TBII (%)                                              66.8±21.4                                                    68.1±26.9                                                 NC
  TSAb (%)                                              2035±118[^\*\*^](#tfn4-kjim-5-1-51-7){ref-type="table-fn"}   254±6[^\*\*^](#tfn4-kjim-5-1-51-7){ref-type="table-fn"}   p\<0.01

NC: not significant, ATD: antithyroid drugs, AMA : antimicrosomal antibody,

Measured by tanned red cell hemagglutination technique using commercial kits (Fujirebio Co., Tokyo, Japan). Values are reciprocals of logarithmic titers.

Meant±SEM

###### 

Serial Changes of Thyroid Function and TSH Receptor Antibodies Activities in Three Patients who Developed Hypothyroidism and Thyroid Stimulation Blocking Antibody After Radioiodine Treatment

  Patient Number   Time[^\*^](#tfn5-kjim-5-1-51-7){ref-type="table-fn"} (month)   T3 (ng/dl)   T4 (ug/dl)   TSH (uU/ml)   TBII (%)   TSAb (%)   TSBAb (%)     Treatment
  ---------------- -------------------------------------------------------------- ------------ ------------ ------------- ---------- ---------- ------------- ---------------
  12               0                                                              250          14.6         \< 0.05       99.8       394        32            ^131^I 15mCi
  3                67                                                             2.0          41.0         91.0          321        34                       
  6                86                                                             3.6          120.0        78.9          84         96         T4 150 ug/d   
  9                176                                                            10.2         1.7          80.5          109        98         \"            
  12               158                                                            11.8         1.2          76.0          133        97         \"            
                                                                                                                                                              
  14               0                                                              315          15.5         \< 0.05       79.8       316        33            ^131^I 8 mCi
  3                102                                                            5.9          14.6         80.9          237        37                       
  6                92                                                             4.5          105.0        85.3          168        83         T4 100 ug/d   
  9                141                                                            10.7         9.1          80.4          109        97         T4 150 ug/d   
  12               169                                                            12.5         0.8          85.7          100        98         \"            
                                                                                                                                                              
  20               0                                                              270          13.0         \< 0.05       90.0       273        25            ^131^I 10 mCi
  3                124                                                            6.2          14.0         80.5          108        96                       
  6                39                                                             2.1          180.0        71.3          99         95         T4 150 ug/d   
  9                166                                                            10.8         1.2          80.7          100        97         \"            
  12               172                                                            12.0         0.8          85.2          105        96         \"            

Time after radioiodine treatment

Normal values: T3 85--200 ng/dl; T4 6.7--13.2 ug/dl; TSH 0.4--4.2 uU/ml; TBII −10.0--15%; TSAb \< 170%; TSBAb \< 37%
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